HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trialsDaniel I. Swerdlow, Rudi G. J. Westendorp, Jorgen Engmann et al.|The Lancet|2014Cited by 709
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation studyAmand F. Schmidt, Andrzej Pająk, Daniel I. Swerdlow et al.|The Lancet Diabetes & Endocrinology|2016Cited by 390